Internal and Emergency Medicine

, Volume 8, Issue 3, pp 205–210

Use and indications of cholestyramine and bile acid sequestrants

  • Franco Scaldaferri
  • Marco Pizzoferrato
  • Francesca Romana Ponziani
  • Giovanni Gasbarrini
  • Antonio Gasbarrini
IM - REVIEW

Abstract

Cholestyramine is a bile acid sequestrant, like colestipol and colesevelam. These molecules are positively charged non-digestible resins that bind to bile acids in the intestine to form an insoluble complex, which is excreted in the feces. They are used mainly for the treatment of primary hypercholesterolemia and hypercholesterolemia associated with mild hypertriglyceridemia, in patients not responding to dietary treatment as well as a second line-treatment for pruritus associated with cholestatic disease, in patients with incomplete biliary obstruction. Several data indicate that modulation of bile acid homeostasis has a good clinical effect in managing diabetes mellitus and the diarrhea from bile acid malabsorption. In this review, we present the “in label” use and indication for these compounds, revisiting the other clinical applications that may benefit from the use of bile acid sequestrants in the near future.

Keywords

Cholestyramine Bile acid sequestrants Colestipol Colesevelam 

References

  1. 1.
    Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol In Adults (2001) Executive summary of the third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III). JAMA 285(19):2486–2497Google Scholar
  2. 2.
    Di Padova C et al (1984) Double-blind placebo-controlled clinical trial of microporous cholestyramine in the treatment of intra- and extra-hepatic cholestasis: relationship between itching and serum bile acids. Methods Find Exp Clin Pharmacol 6(12):773–776PubMedGoogle Scholar
  3. 3.
    Staels B, Kuipers F (2007) Bile acid sequestrants and the treatment of type 2 diabetes mellitus. Drugs 67(10):1383–1392PubMedCrossRefGoogle Scholar
  4. 4.
    Kobayashi M et al (2007) Prevention and treatment of obesity, insulin resistance, and diabetes by bile acid-binding resin. Diabetes 56(1):239–247PubMedCrossRefGoogle Scholar
  5. 5.
    Kamal-Bahl SJ et al (2007) Discontinuation of lipid modifying drugs among commercially insured United States patients in recent clinical practice. Am J Cardiol 99(4):530–534PubMedCrossRefGoogle Scholar
  6. 6.
    Reiner Z (2010) Combined therapy in the treatment of dyslipidemia. Fundam Clin Pharmacol 24(1):19–28PubMedCrossRefGoogle Scholar
  7. 7.
    Bays H, Dujovne C (2003) Colesevelam HCl: a non-systemic lipid-altering drug. Expert Opin Pharmacother 4(5):779–790PubMedGoogle Scholar
  8. 8.
    Graham I et al (2007) European guidelines on cardiovascular disease prevention in clinical practice: executive summary. Fourth Joint Task Force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts). Eur J Cardiovasc Prev Rehabil 14(Suppl 2):E1–E40PubMedCrossRefGoogle Scholar
  9. 9.
    Domanski M et al (2008) Pleiotropic effect of lovastatin, with and without cholestyramine, in the post coronary artery bypass graft (Post CABG) trial. Am J Cardiol 102(8):1023–1027PubMedCrossRefGoogle Scholar
  10. 10.
    The Post Coronary Artery Bypass Graft Trial Investigators (1997) The effect of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation on obstructive changes in saphenous-vein coronary-artery bypass grafts. N Engl J Med 336(3):153–162Google Scholar
  11. 11.
    Brown BG et al (1997) Moderate dose, three-drug therapy with niacin, lovastatin, and colestipol to reduce low-density lipoprotein cholesterol <100 mg/dl in patients with hyperlipidemia and coronary artery disease. Am J Cardiol 80(2):111–115PubMedCrossRefGoogle Scholar
  12. 12.
    Whitney EJ et al (2005) A randomized trial of a strategy for increasing high-density lipoprotein cholesterol levels: effects on progression of coronary heart disease and clinical events. Ann Intern Med 142(2):95–104PubMedGoogle Scholar
  13. 13.
    Ballantyne CM, Miller E, Chitra R (2004) Efficacy and safety of rosuvastatin alone and in combination with cholestyramine in patients with severe hypercholesterolemia: a randomized, open-label, multicenter trial. Clin Ther 26(11):1855–1864PubMedCrossRefGoogle Scholar
  14. 14.
    Lal SM, Katyal A (2002) Effects of nicotinic acid and lovastatin in combination with cholestyramine in renal transplant patients. Mo Med 99(10):580–584PubMedGoogle Scholar
  15. 15.
    Bays HE et al (2006) Effects of colesevelam hydrochloride on low-density lipoprotein cholesterol and high-sensitivity C-reactive protein when added to statins in patients with hypercholesterolemia. Am J Cardiol 97(8):1198–1205PubMedCrossRefGoogle Scholar
  16. 16.
    Davidson MH et al (2010) A 50-week extension study on the safety and efficacy of colesevelam in adults with primary hypercholesterolemia. Am J Cardiovasc Drugs 10(5):305–314PubMedCrossRefGoogle Scholar
  17. 17.
    Bays H, Jones PH (2007) Colesevelam hydrochloride: reducing atherosclerotic coronary heart disease risk factors. Vasc Health Risk Manag 3(5):733–742PubMedGoogle Scholar
  18. 18.
    Huijgen R et al (2010) Colesevelam added to combination therapy with a statin and ezetimibe in patients with familial hypercholesterolemia: a 12-week, multicenter, randomized, double-blind, controlled trial. Clin Ther 32(4):615–625PubMedCrossRefGoogle Scholar
  19. 19.
    Bays H et al (2006) Lipid-lowering effects of colesevelam HCl in combination with ezetimibe. Curr Med Res Opin 22(11):2191–2200PubMedCrossRefGoogle Scholar
  20. 20.
    Knopp RH et al (2006) Lipoprotein effects of combined ezetimibe and colesevelam hydrochloride versus ezetimibe alone in hypercholesterolemic subjects: a pilot study. Metabolism 55(12):1697–1703PubMedCrossRefGoogle Scholar
  21. 21.
    Ballantyne CM et al (2003) Effect of ezetimibe coadministered with atorvastatin in 628 patients with primary hypercholesterolemia: a prospective, randomized, double-blind trial. Circulation 107(19):2409–2415PubMedCrossRefGoogle Scholar
  22. 22.
    Bays H et al (2008) Long-term (48-week) safety of ezetimibe 10 mg/day coadministered with simvastatin compared to simvastatin alone in patients with primary hypercholesterolemia. Curr Med Res Opin 24(10):2953–2966PubMedCrossRefGoogle Scholar
  23. 23.
    Rivers SM et al (2007) Colesevelam hydrochloride-ezetimibe combination lipid-lowering therapy in patients with diabetes or metabolic syndrome and a history of statin intolerance. Endocr Pract 13(1):11–16PubMedGoogle Scholar
  24. 24.
    Harper CR, Jacobson TA (2010) Evidence-based management of statin myopathy. Curr Atheroscler Rep 12(5):322–330PubMedCrossRefGoogle Scholar
  25. 25.
    Pusl T, Beuers U (2005) Extrahepatic manifestations of cholestatic liver diseases: pathogenesis and therapy. Clin Rev Allergy Immunol 28(2):147–157PubMedCrossRefGoogle Scholar
  26. 26.
    Kremer AE et al (2008) Pathogenesis and treatment of pruritus in cholestasis. Drugs 68(15):2163–2182PubMedCrossRefGoogle Scholar
  27. 27.
    Kuiper EM et al (2010) The potent bile acid sequestrant colesevelam is not effective in cholestatic pruritus: results of a double-blind, randomized, placebo-controlled trial. Hepatology 52:1340–1344CrossRefGoogle Scholar
  28. 28.
    Longo M, Crosignani A, Podda M (2001) Hyperlipidemia in chronic cholestatic liver disease. Curr Treat Options Gastroenterol 4(2):111–114PubMedCrossRefGoogle Scholar
  29. 29.
    Garg A, Grundy SM (1994) Cholestyramine therapy for dyslipidemia in non-insulin-dependent diabetes mellitus. A short-term, double-blind, crossover trial. Ann Intern Med 121(6):416–422PubMedGoogle Scholar
  30. 30.
    Bays HE et al (2008) Colesevelam hydrochloride therapy in patients with type 2 diabetes mellitus treated with metformin: glucose and lipid effects. Arch Intern Med 168(18):1975–1983PubMedCrossRefGoogle Scholar
  31. 31.
    Fonseca VA et al (2008) Colesevelam HCl improves glycemic control and reduces LDL cholesterol in patients with inadequately controlled type 2 diabetes on sulfonylurea-based therapy. Diabetes Care 31(8):1479–1484PubMedCrossRefGoogle Scholar
  32. 32.
    Goldberg RB et al (2008) Efficacy and safety of colesevelam in patients with type 2 diabetes mellitus and inadequate glycemic control receiving insulin-based therapy. Arch Intern Med 168(14):1531–1540PubMedCrossRefGoogle Scholar
  33. 33.
    Brufau GKF, Prado K et al (2008) Altered bile acid metabolism in type 2 diabetes mellitus (T2DM). Diabetes 57(A435)Google Scholar
  34. 34.
    Ma K et al (2006) Farnesoid X receptor is essential for normal glucose homeostasis. J Clin Invest 116(4):1102–1109PubMedCrossRefGoogle Scholar
  35. 35.
    Suzuki T et al (2007) Colestimide lowers plasma glucose levels and increases plasma glucagon-like PEPTIDE-1 (7–36) levels in patients with type 2 diabetes mellitus complicated by hypercholesterolemia. J Nippon Med Sch 74(5):338–343PubMedCrossRefGoogle Scholar
  36. 36.
    Staels B, Fonseca VA (2009) Bile acids and metabolic regulation: mechanisms and clinical responses to bile acid sequestration. Diabetes Care 32(Suppl 2):S237–S245PubMedCrossRefGoogle Scholar
  37. 37.
    Rosenstock J et al (2010) Initial combination therapy with metformin and colesevelam for achievement of glycemic and lipid goals in early type 2 diabetes. Endocr Pract 16(4):629–640PubMedCrossRefGoogle Scholar
  38. 38.
    Thompson WG (1975) Treatment of cholerheic diarrhea with cholestyramine and a hydrophilic colloid. Dis Colon Rectum 18(4):304–307PubMedCrossRefGoogle Scholar
  39. 39.
    Pattni S, Walters JR (2009) Recent advances in the understanding of bile acid malabsorption. Br Med Bull 92:79–93PubMedCrossRefGoogle Scholar
  40. 40.
    Hofmann AF, Poley JR (1972) Role of bile acid malabsorption in pathogenesis of diarrhea and steatorrhea in patients with ileal resection. I. Response to cholestyramine or replacement of dietary long chain triglyceride by medium chain triglyceride. Gastroenterology 62(5):918–934PubMedGoogle Scholar
  41. 41.
    Hofmann AF (2009) Chronic diarrhea caused by idiopathic bile acid malabsorption: an explanation at last. Expert Rev Gastroenterol Hepatol 3(5):461–464PubMedCrossRefGoogle Scholar
  42. 42.
    Sinha L et al (1998) Idiopathic bile acid malabsorption: qualitative and quantitative clinical features and response to cholestyramine. Aliment Pharmacol Ther 12(9):839–844PubMedCrossRefGoogle Scholar
  43. 43.
    Westergaard H (2007) Bile Acid malabsorption. Curr Treat Options Gastroenterol 10(1):28–33PubMedCrossRefGoogle Scholar
  44. 44.
    Puleston J, Morgan H, Andreyev J (2005) New treatment for bile salt malabsorption. Gut 54(3):441–442PubMedCrossRefGoogle Scholar
  45. 45.
    Dignass A, Van Assche A, Lindsay JO, Lémann M, Söderholm J et al (2010) The second European evidence-based Consensus on the diagnosis and management of Crohn’s disease: current management. J Crohn’s Colitis 4:28–62CrossRefGoogle Scholar
  46. 46.
    Van Assche G, Dignass A, Reinisch W, Janneke van der Woude C, Sturm A, De Vos M, Guslandi M, Oldenburg B, Dotan I, Marteau P, Ardizzone A, Baumgart DC, D’Haens G, Gionchetti P, Portela F, Vucelic B, Söderholm J, Escher J, Koletzko S, Kolho KL, Lukas M, Mottet C, Tilg H, Vermeire S, Carbonnel F, Cole A, Novacek G, Reinshagen M, Tsianos E, Herrlinger K, Oldenburg B, Bouhnik Y, Kiesslich R, Stange E, Travis S, LindsayJ, European Crohn’s and Colitis Organisation (ECCO) (2010) The second European evidence-based Consensus on the diagnosis and management of Crohn’s disease: special situations. J Crohn’s Colitis 4:63–101Google Scholar
  47. 47.
    Calabrese C et al (2007) Mesalazine with or without cholestyramine in the treatment of microscopic colitis: randomized controlled trial. J Gastroenterol Hepatol 22(6):809–814PubMedCrossRefGoogle Scholar
  48. 48.
    Jacobsen O et al (1985) Effect of enterocoated cholestyramine on bowel habit after ileal resection: a double blind crossover study. Br Med J (Clin Res Ed) 290(6478):1315–1318CrossRefGoogle Scholar
  49. 49.
    Shatnawei A et al (2010) Intestinal failure management at the Cleveland Clinic. Arch Surg 145(6):521–527PubMedCrossRefGoogle Scholar
  50. 50.
    Matarese LE, Steiger E (2006) Dietary and medical management of short bowel syndrome in adult patients. J Clin Gastroenterol 40(Suppl 2):S85–S93PubMedCrossRefGoogle Scholar

Copyright information

© SIMI 2011

Authors and Affiliations

  • Franco Scaldaferri
    • 1
  • Marco Pizzoferrato
    • 1
  • Francesca Romana Ponziani
    • 1
  • Giovanni Gasbarrini
    • 2
  • Antonio Gasbarrini
    • 1
  1. 1.Catholic University of RomeRomeItaly
  2. 2.Fondazione Ricerca in Medicina ONLUSBolognaItaly

Personalised recommendations